Mounjaro Maker Eli Lilly Inks $2.7 Billion AI Drug Discovery Deal

• US pharma giant Eli Lilly partners with Hong Kong-listed Insilico Medicine for AI-driven drug discovery.
• The deal, potentially worth up to US$2.75 billion, leverages Insilico's AI engine to accelerate novel therapeutic development.
• This collaboration expands on existing agreements, including a 2023 software licensing deal.
• Generative AI's data processing capabilities offer significant promise for the medical sector.
• Insilico will receive an upfront payment of US$115 million, with further collaboration on Lilly-selected targets.